We are pleased to announce that our small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd (STA) began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.  The site will employ more than 500 scientists and will add more than 1,000 m3 of reactor volume, doubling STA’s existing R&D capacity and quadrupling its manufacturing capacity.  Besides adding capacity, this state-of-the-art integrated campus will provide a unique one-site solution for STA customers to advance their active pharmaceutical ingredients (APIs) and advanced intermediates through preclinical and clinical development to global commercial launch.  The new site in Changzhou brings our customers added capacity, greater flexibility, and the unsurpassed quality of WuXi’s operations.


Related Articles:

  1. WuXi’s STA Subsidiary Receives First Approval from Japanese Regulatory Authorities
  2. WuXi Facility Passes U.S. FDA Inspection for Manufacture of API